California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Recruiting
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UCLA Hematology/Oncology - Santa Monica ( Site 0140), Los Angeles, California
Conditions: Gastroesophageal Cancer
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Recruiting
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UCSD Moores Cancer Center ( Site 0039), La Jolla, California
Conditions: Prostatic Neoplasms, Castration-Resistant
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Recruiting
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California
Conditions: Advanced Solid Tumor
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
Recruiting
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Scripps Health, La Jolla, California
Conditions: Coronary Artery Disease, Coronary Artery Calcification
RCT of a Weighted Blanket to Reduce Pain in Veterans With Chronic Pain
Recruiting
Chronic pain is a major health concern for returning Veterans and is associated with decreases in quality of life. In addition, chronic pain is often accompanied by significant disturbance in sleep. Sensory interventions may offer effective, low-cost complementary tools for chronic pain and sleep disturbance in Veterans. Weighted Blankets (WB)- blankets sewn with weighted material inside to provide widespread pressure to the body- are a low-cost wellness product used for anxiety and sleep. WBs h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Chronic Pain, Sleep Disturbance
The Actuate-CBC Study
Recruiting
The study team will use implementation science to accelerate the uptake of teleconsultationfor burn patients by 1) examining the relationships between clinician perceptions of acceptability, feasibility, intention to use, and actual use of burn teleconsultation 2) identifying the optimal process for burn teleconsultation and the barriers and facilitators for its use during a crisis or prolonged care situation, and 3) designing and testing the effectiveness of a specific, tailored burn teleconsul... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UCI Health Regional Burn Center, Orange, California
Conditions: Telemedicine
Gravitas Feeding Tube System Placement Validation in Neonates
Recruiting
The purpose of this study is to validate the Gravitas Feeding Tube System Placement Algorithm for NICU patients and to evaluate the safety and effectiveness of the Gravitas Feeding Tube in the neonate population for the administration of nutrition, fluids and medications.
Gender:
ALL
Ages:
Between 0 weeks and 18 weeks
Trial Updated:
07/25/2025
Locations: Lucile Packard (Stanford) Children's Hospital, Stanford, California
Conditions: Nasogastric Tube
Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
Recruiting
The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo the PEF procedure and be followed per institutional standard of care.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/25/2025
Locations: Eisenhower Medical Center, Rancho Mirage, California
Conditions: Soft Tissue Lesion
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
Recruiting
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
Recruiting
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/25/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Insomnia
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Clinical Trial Site, San Diego, California
Conditions: Early-Onset Alzheimer Disease
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certa... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/25/2025
Locations: Los Angeles General Medical Center, Los Angeles, California
Conditions: Metastatic NUT Carcinoma, Unresectable NUT Carcinoma, Advanced NUT Carcinoma